Sunny Pharmtech Inc.
TTPEX:66769.97
TWD
-0.33
(-3.20%)
ISIN
TW0006676000
Return %
Stock
S&P 500
1Y
-28.79
14.20
3Y
-69.92
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yung Lien Wu
- Full Time Employees
- 160
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- No.255,Longyuan 1st Road Taoyuan TY Taiwan 325002
- IPO Date
- Jan 19, 2022
- Website
- sunnypharmtech.com
- Similar Companies
- Business
- Sunny Pharmtech Inc. functions as an integrated specialty pharmaceutical enterprise, concentrating on the global research, development, manufacturing, and commercialization of both active pharmaceutical ingredients and finished drug products. The company specializes in creating complex, high-barrier generic drugs and 505(b)(2) products, alongside providing comprehensive Contract Development and Manufacturing Organization (CDMO) support for a variety of dosage forms. Their product range features items like anesthetic ointments, vitamin B12 injections, nitrofurantoin capsules for anti-infective treatment, and aminocaproic acid formulations for hematological conditions. Recent significant achievements include securing U.S. FDA approvals for a multi-cancer injection (CPA-I), an aminocaproic acid solution (AMA-S), and diazepam injection (DZP-I). Sunny Pharmtech is also actively expanding its international presence through licensing agreements for products such as carboprost tromethamine injection in various markets and advancing pipeline therapies for oncology, ulcerative colitis, and rare cardiovascular diseases via strategic partnerships. Founded in 2014, the company is headquartered in Taoyuan, Taiwan, operating U.S. FDA-inspected facilities to deliver high-quality healthcare solutions worldwide.